Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.

@article{Punekar2010CosteffectivenessOS,
  title={Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.},
  author={Y S Punekar and Thomas Sunderland and Neil Stephen Hawkins and James N Lindsay},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2010},
  volume={13 2},
  pages={188-95}
}
BACKGROUND Infliximab recently became the only biologic approved for use in pediatric patients with severe active Crohn's disease (CD). OBJECTIVES To estimate the cost-effectiveness of scheduled maintenance treatment with infliximab compared with standard care in children suffering from severe active CD over 5 years from the UK National Health Service perspective. METHODS A Markov model was constructed to simulate the progression of a hypothetical cohort of CD children through predefined… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research • 2011
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…